3Wills KN, Huang WM, Harris MP, et al. Gene therapy for hepatocellular carcinoma: chemosensitivity conferred by adenovirus - mediated transfer of the HSV- 1 thymidine kinase gene[J]. Cancer Gene Ther, 1995,2 (3): 191 - 197.
4Furutani M, Iida T, Yoshida T, et al. Group Ⅱ chaperonin in a thermophilic methanogen, Methanococcus thermolithotrophicus. Chaperone activity and filament -forming ability[J] .J Bil Chem, 1998, 273(43):28399 - 28407.
5Hupkova M, Blahova J, Kralikova J, et al. Transferable resistance to beta- lactams in a nosocomial strain of Xanthomonas maltophilia[J]. Antimicrob Agents Chemother, 1995, 39(4): 1011 - 1012.
6Vollmer CMJ r, Eilber FC, Butterfield LH, et al. Alpha- fetoproteinspecific genetic immunotherapy for hepatocellular carcinima[ J ]. Cancer Res, 1999,59(13) :3064 - 3069.
7Hui AM, Sakamoto M, Kanai Y, et al. Inactivation of p16INK4 in hepatocellular carcinoma[J]. Hepatology, 1996,24(3) :575 - 579.
8Hui AM, Li X, Makuuchi M, et al. Over- expression and lack of retinoblastoma protein are associated with ttnor progression and metastasis in hepatocellular carcinoma[J]. Int J Cancer, 1999, 84(6) :604 - 608.
9Rashid A, Wang JS, Qian GS, et al. Genetic alterations in hepatocellular carcinomas: association between loss of chromosome 4q and p53 gene mutations[J]. Br J Cancer, 1999, 80( 1 - 2): 59 - 66.
10Hui AM, Kanai Y, Sakamoto M, et al. Reduced p21(WAF1/CIP1) expression and p53 mutation in hepatocellular carcinomas[J]. Hepatology,1997, 25(3) :575 - 579.
2Edelstein DM, Aharonoff GB, Karp A, et al. Effect of postope- raeive delirium on ourcome after hip fracture[J]. Clin Orthop Relat Res, 2004,422 : 195- 200.
